Hereditary Transthyretin Amyloidosis Market Report 2026
Download Free Sample Buy Now
Hereditary Transthyretin Amyloidosis Market Global Report 2026 Market Report Infographic Image

Published : March 2026

Pages : 175

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Hereditary Transthyretin Amyloidosis Market Report 2026

Global Outlook – By Type (Oral, Subcutaneous Injection, Other Types), By Drug Class (RNAi Agents (Patisiran), Small Interfering RNAs (siRNAs) (Vutrisiran)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Application (Hospital, Clinic, Other Applications) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
Purchase This Report Download Sample PDF
Item added to cart!

Hereditary Transthyretin Amyloidosis Market Overview

• Hereditary Transthyretin Amyloidosis market size has reached to $1.49 billion in 2025

• Expected to grow to $2.28 billion in 2030 at a compound annual growth rate (CAGR) of 8.9%

• Growth Driver: Rising Geriatric Population Driving The Growth Of The Market Due To Increasing Disease Prevalence

• Market Trend: Innovative RNAi Therapeutics Driving Advancements In The Market

• North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Hereditary Transthyretin Amyloidosis Market?

Hereditary transthyretin amyloidosis is a rare, inherited disorder caused by mutations in the TTR gene, leading to the misfolding and accumulation of transthyretin protein as amyloid deposits in organs. This condition primarily affects the nervous system, heart, and other tissues, causing progressive neuropathy and cardiomyopathy.

The main types of hereditary transthyretin amyloidosis are oral, subcutaneous injection, and other types. Oral administration, involving tablets, capsules, or liquids, offers a convenient and patient-friendly treatment option for hATTR amyloidosis, improving accessibility and adherence. The drug classes used in the treatment of hATTR amyloidosis include RNAi agents, such as patisiran, and small interfering RNAs (siRNAs) like vutrisiran. These therapies are distributed through hospital pharmacies and retail pharmacies and used in applications such as hospitals, clinics, and others.

Hereditary Transthyretin Amyloidosis Market Global Report 2026 Market Report bar graph

What Is The Hereditary Transthyretin Amyloidosis Market Size and Share 2026?

The hereditary transthyretin amyloidosis market size has grown strongly in recent years. It will grow from $1.49 billion in 2025 to $1.62 billion in 2026 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to increasing clinical recognition of attr amyloidosis, availability of tafamidis therapy, expansion of specialized neurology and cardiology centers, improved genetic testing for ttr mutations, rising patient registry programs.

What Is The Hereditary Transthyretin Amyloidosis Market Growth Forecast?

The hereditary transthyretin amyloidosis market size is expected to see strong growth in the next few years. It will grow to $2.28 billion in 2030 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to expansion of next-generation gene therapies, increasing investment in rare disease research, growing adoption of precision medicine approaches, rising development of crispr-based treatments, improved disease outcome monitoring technologies. Major trends in the forecast period include increasing adoption of gene silencing therapies, rising use of rnAI-based treatments, growing focus on early cardiac and neurological diagnosis, expansion of oral therapeutic options, enhanced long-term disease management strategies.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

Global Hereditary Transthyretin Amyloidosis Market Segmentation

1) By Type: Oral, Subcutaneous Injection, Other Types

2) By Drug Class: RNAi Agents (Patisiran), Small Interfering RNAs (siRNAs) (Vutrisiran)

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies

4) By Application: Hospital, Clinic, Other Applications

Subsegments:

1) By Oral: Tafamidis, Experimental Oral Therapies

2) By Subcutaneous Injection: Inotersen, Vutrisiran

3) By Other Types: Intravenous Therapies, Gene Silencing Therapies, CRISPR-Based Therapies

What Is The Driver Of The Hereditary Transthyretin Amyloidosis Market?

The growing geriatric population is expected to propel the growth of the hereditary transthyretin amyloidosis market going forward. The geriatric population refers to individuals aged 65 and older, often requiring specialized healthcare and support due to aging. The geriatric population is growing due to increasing life expectancy driven by advancements in healthcare and living conditions. Hereditary transthyretin amyloidosis (hATTR) significantly impacts the geriatric population by causing progressive neuropathy and cardiomyopathy, leading to increased morbidity in aging individuals. For instance, in January 2024, according to the Population Reference Bureau, a US-based nonprofit organization, the US population aged 65 and older is expected to grow from 58 million in 2022 to 82 million by 2050, marking a 47% increase. Therefore, the growing geriatric population is driving the growth of the hereditary transthyretin amyloidosis industry.

Key Players In The Global Hereditary Transthyretin Amyloidosis Market

Major companies operating in the hereditary transthyretin amyloidosis market are Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BridgeBio Pharma Inc., Pfizer Inc., Eli Lilly and Company, Intellia Therapeutics Inc., Regeneron Pharmaceuticals Inc., AstraZeneca plc, Novartis AG, Roche Holding AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Bristol Myers Squibb, Merck and Co Inc., Johnson and Johnson, AbbVie Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Amgen Inc.

Global Hereditary Transthyretin Amyloidosis Market Trends and Insights

Major companies operating in the hereditary transthyretin amyloidosis market are developing innovative therapeutics, such as RNAi therapeutics, to target and reduce the production of transthyretin (TTR) protein. RNAi therapeutics are a class of drugs that use RNA interference technology to silence specific genes, thereby reducing the production of disease-causing proteins. For instance, in October 2024, Alnylam Pharmaceuticals, Inc., a US-based biopharmaceutical company, submitted a supplemental new drug application (sNDA) to the US FDA for Vutrisiran (AMVUTTRA) as a treatment for transthyretin amyloidosis with cardiomyopathy. This submission underscores its innovative RNAi therapeutic approach, designed to target and reduce transthyretin (TTR) protein, a key factor in disease progression. Vutrisiran’s subcutaneous administration offers a more convenient and patient-friendly dosing regimen compared to traditional intravenous treatments, positioning it as a potentially transformative option for individuals with this serious condition.

Need data on a specific region in this market?
Request Regional Data

What Are Latest Mergers And Acquisitions In The Hereditary Transthyretin Amyloidosis Market?

In July 2023, Ionis Pharmaceuticals, Inc., a US-based biopharmaceutical company specializing in RNA-targeted drug discovery and development, partnered with AstraZeneca plc to jointly develop and market eplontersen for the treatment of transthyretin amyloidosis (ATTR) in the U.S. This collaboration also seeks to expand global access to the treatment by leveraging AstraZeneca’s strong commercial presence, particularly in Latin America and other international markets. AstraZeneca plc. is a UK-based biopharmaceutical company dedicated to the discovery, development, and commercialization of prescription medicines.

Regional Outlook

North America was the largest region in the hereditary transthyretin amyloidosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Hereditary Transthyretin Amyloidosis Market?

The hereditary transthyretin amyloidosis market consists of revenues earned by entities by providing services such as diagnostic services, treatment services, and genetic counseling services. The market value includes the value of related goods sold by the service provider or included within the service offering. The hereditary transthyretin amyloidosis market also includes sales of genetic testing kits, imaging technologies, biomarkers, and assays. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Hereditary Transthyretin Amyloidosis Market Report 2026?

The hereditary transthyretin amyloidosis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the hereditary transthyretin amyloidosis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abdul Wasay

Hereditary Transthyretin Amyloidosis Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2026 $1.62 billion
Revenue Forecast In 2035 $2.28 billion
Growth Rate CAGR of 9.0% from 2026 to 2035
Base Year For Estimation 2025
Actual Estimates/Historical Data 2020-2025
Forecast Period 2026 - 2030 - 2035
Market Representation Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered Type, Drug Class, Distribution Channel, Application
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BridgeBio Pharma Inc., Pfizer Inc., Eli Lilly and Company, Intellia Therapeutics Inc., Regeneron Pharmaceuticals Inc., AstraZeneca plc, Novartis AG, Roche Holding AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Bristol Myers Squibb, Merck and Co Inc., Johnson and Johnson, AbbVie Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Amgen Inc.
Customization ScopeRequest for Customization
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Hereditary Transthyretin Amyloidosis Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Hereditary Transthyretin Amyloidosis Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Hereditary Transthyretin Amyloidosis Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global Hereditary Transthyretin Amyloidosis Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics & Precision Medicine

4.1.2 Artificial Intelligence & Autonomous Intelligence

4.1.3 Digitalization, Cloud, Big Data & Cybersecurity

4.1.4 Industry 4.0 & Intelligent Manufacturing

4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems

4.2. Major Trends

4.2.1 Increasing Adoption Of Gene Silencing Therapies

4.2.2 Rising Use Of Rnai-Based Treatments

4.2.3 Growing Focus On Early Cardiac And Neurological Diagnosis

4.2.4 Expansion Of Oral Therapeutic Options

4.2.5 Enhanced Long-Term Disease Management Strategies

5. Hereditary Transthyretin Amyloidosis Market Analysis Of End Use Industries

5.1 Hospitals

5.2 Specialty Clinics

5.3 Cardiology Centers

5.4 Neurology Centers

5.5 Research Institutions

6. Hereditary Transthyretin Amyloidosis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Hereditary Transthyretin Amyloidosis Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Hereditary Transthyretin Amyloidosis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Hereditary Transthyretin Amyloidosis Market Size, Comparisons And Growth Rate Analysis

7.3. Global Hereditary Transthyretin Amyloidosis Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global Hereditary Transthyretin Amyloidosis Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Hereditary Transthyretin Amyloidosis Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Hereditary Transthyretin Amyloidosis Market Segmentation

9.1. Global Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Oral, Subcutaneous Injection, Other Types

9.2. Global Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

RNAi Agents (Patisiran), Small Interfering RNAs (siRNAs) (Vutrisiran)

9.3. Global Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospital Pharmacies, Retail Pharmacies

9.4. Global Hereditary Transthyretin Amyloidosis Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospital, Clinic, Other Applications

9.5. Global Hereditary Transthyretin Amyloidosis Market, Sub-Segmentation Of Oral, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Tafamidis, Experimental Oral Therapies

9.6. Global Hereditary Transthyretin Amyloidosis Market, Sub-Segmentation Of Subcutaneous Injection, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Inotersen, Vutrisiran

9.7. Global Hereditary Transthyretin Amyloidosis Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Intravenous Therapies, Gene Silencing Therapies, CRISPR-Based Therapies

10. Hereditary Transthyretin Amyloidosis Market Regional And Country Analysis

10.1. Global Hereditary Transthyretin Amyloidosis Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global Hereditary Transthyretin Amyloidosis Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Hereditary Transthyretin Amyloidosis Market

11.1. Asia-Pacific Hereditary Transthyretin Amyloidosis Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Hereditary Transthyretin Amyloidosis Market

12.1. China Hereditary Transthyretin Amyloidosis Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Hereditary Transthyretin Amyloidosis Market

13.1. India Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Hereditary Transthyretin Amyloidosis Market

14.1. Japan Hereditary Transthyretin Amyloidosis Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

14.2. Japan Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Hereditary Transthyretin Amyloidosis Market

15.1. Australia Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Hereditary Transthyretin Amyloidosis Market

16.1. Indonesia Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Hereditary Transthyretin Amyloidosis Market

17.1. South Korea Hereditary Transthyretin Amyloidosis Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

17.2. South Korea Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Hereditary Transthyretin Amyloidosis Market

18.1. Taiwan Hereditary Transthyretin Amyloidosis Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

18.2. Taiwan Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Hereditary Transthyretin Amyloidosis Market

19.1. South East Asia Hereditary Transthyretin Amyloidosis Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

19.2. South East Asia Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Hereditary Transthyretin Amyloidosis Market

20.1. Western Europe Hereditary Transthyretin Amyloidosis Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

20.2. Western Europe Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Hereditary Transthyretin Amyloidosis Market

21.1. UK Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Hereditary Transthyretin Amyloidosis Market

22.1. Germany Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Hereditary Transthyretin Amyloidosis Market

23.1. France Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Hereditary Transthyretin Amyloidosis Market

24.1. Italy Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Hereditary Transthyretin Amyloidosis Market

25.1. Spain Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Hereditary Transthyretin Amyloidosis Market

26.1. Eastern Europe Hereditary Transthyretin Amyloidosis Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

26.2. Eastern Europe Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Hereditary Transthyretin Amyloidosis Market

27.1. Russia Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Hereditary Transthyretin Amyloidosis Market

28.1. North America Hereditary Transthyretin Amyloidosis Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

28.2. North America Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Hereditary Transthyretin Amyloidosis Market

29.1. USA Hereditary Transthyretin Amyloidosis Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

29.2. USA Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Hereditary Transthyretin Amyloidosis Market

30.1. Canada Hereditary Transthyretin Amyloidosis Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

30.2. Canada Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Hereditary Transthyretin Amyloidosis Market

31.1. South America Hereditary Transthyretin Amyloidosis Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

31.2. South America Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Hereditary Transthyretin Amyloidosis Market

32.1. Brazil Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Hereditary Transthyretin Amyloidosis Market

33.1. Middle East Hereditary Transthyretin Amyloidosis Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

33.2. Middle East Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Hereditary Transthyretin Amyloidosis Market

34.1. Africa Hereditary Transthyretin Amyloidosis Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

34.2. Africa Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Hereditary Transthyretin Amyloidosis Market Regulatory and Investment Landscape

36. Hereditary Transthyretin Amyloidosis Market Competitive Landscape And Company Profiles

36.1. Hereditary Transthyretin Amyloidosis Market Competitive Landscape And Market Share 2024

36.1.1. Top 10 Companies (Ranked by revenue/share)

36.2. Hereditary Transthyretin Amyloidosis Market - Company Scoring Matrix

36.2.1. Market Revenues

36.2.2. Product Innovation Score

36.2.3. Brand Recognition

36.3. Hereditary Transthyretin Amyloidosis Market Company Profiles

36.3.1. Alnylam Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.2. Ionis Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.3. BridgeBio Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.4. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.5. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

37. Hereditary Transthyretin Amyloidosis Market Other Major And Innovative Companies

Intellia Therapeutics Inc., Regeneron Pharmaceuticals Inc., AstraZeneca plc, Novartis AG, Roche Holding AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Bristol Myers Squibb, Merck and Co Inc., Johnson and Johnson, AbbVie Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Amgen Inc.

38. Global Hereditary Transthyretin Amyloidosis Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Hereditary Transthyretin Amyloidosis Market

40. Hereditary Transthyretin Amyloidosis Market High Potential Countries, Segments and Strategies

40.1 Hereditary Transthyretin Amyloidosis Market In 2030 - Countries Offering Most New Opportunities

40.2 Hereditary Transthyretin Amyloidosis Market In 2030 - Segments Offering Most New Opportunities

40.3 Hereditary Transthyretin Amyloidosis Market In 2030 - Growth Strategies

40.3.1 Market Trend Based Strategies

40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations

41.2. Currencies

41.3. Historic And Forecast Inflation Rates

41.4. Research Inquiries

41.5. The Business Research Company

41.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Hereditary Transthyretin Amyloidosis Market, Overview Of Key Products - Product Examples
  • Table 2: Global Hereditary Transthyretin Amyloidosis Market Attractiveness, Factor-Wise Evaluation
  • Table 3: Global Hereditary Transthyretin Amyloidosis Market, Supply Chain Analysis
  • Table 4: Global Hereditary Transthyretin Amyloidosis Market, Major Raw Material Providers
  • Table 5: Global Hereditary Transthyretin Amyloidosis Market, Major Resource Providers
  • Table 6: Global Hereditary Transthyretin Amyloidosis Market, Major Manufacturers (Suppliers)
  • Table 7: Global Hereditary Transthyretin Amyloidosis Market, Major Distributors And Channel Partners
  • Table 8: Global Hereditary Transthyretin Amyloidosis Market, Key Technologies & Future Trends
  • Table 9: Global Hereditary Transthyretin Amyloidosis Market, Major Trends
  • Table 10: Global Hereditary Transthyretin Amyloidosis Market, Major End Users
  • Table 11: Global Hereditary Transthyretin Amyloidosis Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Table 12: Global Hereditary Transthyretin Amyloidosis Historic Market Growth, 2020-2025, $ Billion
  • Table 13: Global Hereditary Transthyretin Amyloidosis Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Table 14: Global Hereditary Transthyretin Amyloidosis Market - TAM, US$ Billion, 2025
  • Table 15: Global Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 16: Global Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 17: Global Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 18: Global Hereditary Transthyretin Amyloidosis Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 19: Global Hereditary Transthyretin Amyloidosis Market, Sub-Segmentation Of Oral, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 20: Global Hereditary Transthyretin Amyloidosis Market, Sub-Segmentation Of Subcutaneous Injection, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 21: Global Hereditary Transthyretin Amyloidosis Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 22: Global Hereditary Transthyretin Amyloidosis Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 23: Global Hereditary Transthyretin Amyloidosis Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 24: Asia-Pacific, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 25: Asia-Pacific, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 26: Asia-Pacific, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 27: China, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 28: China, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 29: China, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 30: India, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 31: India, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 32: India, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 33: Japan, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 34: Japan, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 35: Japan, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 36: Australia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 37: Australia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 38: Australia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 39: Indonesia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 40: Indonesia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 41: Indonesia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 42: South Korea, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 43: South Korea, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 44: South Korea, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 45: Taiwan, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 46: Taiwan, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 47: Taiwan, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 48: South East Asia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 49: South East Asia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 50: South East Asia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 51: Western Europe, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 52: Western Europe, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 53: Western Europe, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 54: UK, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 55: UK, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 56: UK, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 57: Germany, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 58: Germany, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 59: Germany, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 60: France, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 61: France, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 62: France, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 63: Italy, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 64: Italy, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 65: Italy, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 66: Spain, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 67: Spain, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 68: Spain, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 69: Eastern Europe, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 70: Eastern Europe, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 71: Eastern Europe, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 72: Russia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 73: Russia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 74: Russia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 75: North America, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 76: North America, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 77: North America, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 78: USA, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 79: USA, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 80: USA, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 81: Canada, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 82: Canada, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 83: Canada, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 84: South America, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 85: South America, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 86: South America, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 87: Brazil, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 88: Brazil, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 89: Brazil, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 90: Middle East, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 91: Middle East, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 92: Middle East, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 93: Africa, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 94: Africa, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 95: Africa, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 96: Global Hereditary Transthyretin Amyloidosis Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Table 97: Global Hereditary Transthyretin Amyloidosis Market - Company Scoring Matrix
  • Table 98: Alnylam Pharmaceuticals Inc. Financial Performance
  • Table 99: Ionis Pharmaceuticals Inc. Financial Performance
  • Table 100: BridgeBio Pharma Inc. Financial Performance
  • Table 101: Pfizer Inc. Financial Performance
  • Table 102: Eli Lilly and Company Financial Performance
  • Table 103: Global Hereditary Transthyretin Amyloidosis Market, Competitive Benchmarking (In USD Billions)
  • Table 104: Global Hereditary Transthyretin Amyloidosis Market, Competitive Dashboard
  • Table 105: Global Hereditary Transthyretin Amyloidosis Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Table 106: Global, Hereditary Transthyretin Amyloidosis Market Size Gain ($ Billion), Segmentation By Type, 2025 – 2030
  • Table 107: Global, Hereditary Transthyretin Amyloidosis Market Size Gain ($ Billion), Segmentation By Drug Class, 2025 – 2030
  • Table 108: Global, Hereditary Transthyretin Amyloidosis Market Size Gain ($ Billion), Segmentation By Distribution Channel, 2025 – 2030

List Of Figures

    Figure 1: Global Hereditary Transthyretin Amyloidosis Market, Overview Of Key Products - Product Examples
  • Figure 2: Global Hereditary Transthyretin Amyloidosis Market Attractiveness, Factor-Wise Evaluation
  • Figure 3: Global Hereditary Transthyretin Amyloidosis Market, Supply Chain Analysis
  • Figure 4: Global Hereditary Transthyretin Amyloidosis Market, Major Raw Material Providers
  • Figure 5: Global Hereditary Transthyretin Amyloidosis Market, Major Resource Providers
  • Figure 6: Global Hereditary Transthyretin Amyloidosis Market, Major Manufacturers (Suppliers)
  • Figure 7: Global Hereditary Transthyretin Amyloidosis Market, Major Distributors And Channel Partners
  • Figure 8: Global Hereditary Transthyretin Amyloidosis Market, Key Technologies & Future Trends
  • Figure 9: Global Hereditary Transthyretin Amyloidosis Market, Major Trends
  • Figure 10: Global Hereditary Transthyretin Amyloidosis Market, Major End Users
  • Figure 11: Global Hereditary Transthyretin Amyloidosis Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Figure 12: Global Hereditary Transthyretin Amyloidosis Historic Market Growth, 2020-2025, $ Billion
  • Figure 13: Global Hereditary Transthyretin Amyloidosis Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Figure 14: Global Hereditary Transthyretin Amyloidosis Market - TAM, US$ Billion, 2025
  • Figure 15: Global Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 16: Global Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 17: Global Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 18: Global Hereditary Transthyretin Amyloidosis Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 19: Global Hereditary Transthyretin Amyloidosis Market, Sub-Segmentation Of Oral, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 20: Global Hereditary Transthyretin Amyloidosis Market, Sub-Segmentation Of Subcutaneous Injection, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 21: Global Hereditary Transthyretin Amyloidosis Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 22: Global Hereditary Transthyretin Amyloidosis Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 23: Global Hereditary Transthyretin Amyloidosis Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 24: Asia-Pacific, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 25: Asia-Pacific, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 26: Asia-Pacific, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 27: China, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 28: China, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 29: China, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 30: India, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 31: India, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 32: India, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 33: Japan, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 34: Japan, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 35: Japan, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 36: Australia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 37: Australia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 38: Australia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 39: Indonesia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 40: Indonesia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 41: Indonesia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 42: South Korea, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 43: South Korea, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 44: South Korea, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 45: Taiwan, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 46: Taiwan, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 47: Taiwan, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 48: South East Asia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 49: South East Asia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 50: South East Asia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 51: Western Europe, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 52: Western Europe, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 53: Western Europe, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 54: UK, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 55: UK, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 56: UK, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 57: Germany, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 58: Germany, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 59: Germany, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 60: France, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 61: France, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 62: France, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 63: Italy, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 64: Italy, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 65: Italy, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 66: Spain, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 67: Spain, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 68: Spain, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 69: Eastern Europe, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 70: Eastern Europe, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 71: Eastern Europe, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 72: Russia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 73: Russia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 74: Russia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 75: North America, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 76: North America, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 77: North America, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 78: USA, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 79: USA, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 80: USA, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 81: Canada, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 82: Canada, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 83: Canada, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 84: South America, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 85: South America, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 86: South America, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 87: Brazil, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 88: Brazil, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 89: Brazil, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 90: Middle East, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 91: Middle East, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 92: Middle East, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 93: Africa, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 94: Africa, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 95: Africa, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 96: Global Hereditary Transthyretin Amyloidosis Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Figure 97: Global Hereditary Transthyretin Amyloidosis Market - Company Scoring Matrix
  • Figure 98: Alnylam Pharmaceuticals Inc. Financial Performance
  • Figure 99: Ionis Pharmaceuticals Inc. Financial Performance
  • Figure 100: BridgeBio Pharma Inc. Financial Performance
  • Figure 101: Pfizer Inc. Financial Performance
  • Figure 102: Eli Lilly and Company Financial Performance
  • Figure 103: Global Hereditary Transthyretin Amyloidosis Market, Competitive Benchmarking (In USD Billions)
  • Figure 104: Global Hereditary Transthyretin Amyloidosis Market, Competitive Dashboard
  • Figure 105: Global Hereditary Transthyretin Amyloidosis Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Figure 106: Global, Hereditary Transthyretin Amyloidosis Market Size Gain ($ Billion), Segmentation By Type, 2025 – 2030
  • Figure 107: Global, Hereditary Transthyretin Amyloidosis Market Size Gain ($ Billion), Segmentation By Drug Class, 2025 – 2030
  • Figure 108: Global, Hereditary Transthyretin Amyloidosis Market Size Gain ($ Billion), Segmentation By Distribution Channel, 2025 – 2030

Global Acute Care Telemedicine Market Forecast to Reach $66.59 Billion by 2029, Driven by 17.7% CAGR

Read More About Global Acute Care Telemedicine Market Forecast to Reach $66.59 Billion by 2029, Driven by 17.7% CAGR

2025–2029 Assistive Technology For Low Vision Market Outlook: Regional Trends and Growth Forecast

Read More About 2025–2029 Assistive Technology For Low Vision Market Outlook: Regional Trends and Growth Forecast

Global Biotechnology And Pharmaceutical Services Outsourcing Market Forecast to Reach $94.91 Billion by 2029, Driven by 7.2% CAGR

Read More About Global Biotechnology And Pharmaceutical Services Outsourcing Market Forecast to Reach $94.91 Billion by 2029, Driven by 7.2% CAGR

Cancer Treatment Facilities Market Revenue Outlook: Strategic Insights and Forecast to 2029

Read More About Cancer Treatment Facilities Market Revenue Outlook: Strategic Insights and Forecast to 2029

CAGR of 10.4% Projected for Catastrophic Antiphospholipid Syndrome Market From 2025 to 2029

Read More About CAGR of 10.4% Projected for Catastrophic Antiphospholipid Syndrome Market From 2025 to 2029

Latest Market Developments in Clinical Risk Grouping Solution Industry: Forecast 2025–2029

Read More About Latest Market Developments in Clinical Risk Grouping Solution Industry: Forecast 2025–2029

2025–2029 Clinical Trial Investigative Site Network Market Outlook: Regional Trends and Growth Forecast

Read More About 2025–2029 Clinical Trial Investigative Site Network Market Outlook: Regional Trends and Growth Forecast

Future Demand and Leading Companies Shaping the Common Cold Market to 2029

Read More About Future Demand and Leading Companies Shaping the Common Cold Market to 2029

Transthyretin Amyloidosis Treatment Market Report 2026 - Global Outlook – By Type (Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN), Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)), By Drug (Tafamidis, Pa...

Atrophic Glossitis Treatment Market Report 2026 - Global Outlook – By Treatment Type (Medications, Topical Treatments, Nutritional Supplements, Oral Care Products), By Symptoms (Inflammation, Discoloration, Itching, Burn...

Progressive Ataxia And Weakness Disorders Market Report 2026 - Global Outlook – By Type (Progressive Ataxia, Progressive Weakness Disorders), By Technology (Small Molecule, Monoclonal Antibody, Other Technology), By Dist...

Alzheimer's Drugs Market Report 2026 - Global Outlook – By Drugs (Donepezil, Rivastigmine, Galantamine, Memantine), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Application (Early To ...

Neurotoxin Market Report 2026 - Global Outlook – By Product Type (Botox, Dysport, Xeomin, Other Products), By Application (Therapeutic, Aesthetic), By End User (Hospitals, Specialty Clinics, Dermatology Clinics, Other En...

Retinitis Pigmentosa Market Report 2026 - Global Outlook – By Type (Autosomal Recessive, Autosomal Dominant, X-Linked), By Treatment (Vitamin A, Docosahexaenoic Acid (DHA), Calcium Channel Blockers, Gene Therapy, Retinal...

Hereditary Cancer Testing Market Report 2026 - Global Outlook – By Test Type (Multi Panel Test, Single-Site Genetic Test), By Indication (Breast Cancer, Ovarian Cancer, Colorectal Cancer, Other Indications), By End user ...

Homeopathy Market Report 2026 - Global Outlook – By Type (Dilutions, Tinctures, Biochemics, Ointments, Tablets, Other Types), By Source (Plants, Animals, Minerals), By Distribution Channel (Homeopathic Clinics, Retailers...

Frequently Asked Questions

The Hereditary Transthyretin Amyloidosis market was valued at $1.49 billion in 2025, increased to $1.62 billion in 2026, and is projected to reach $2.28 billion by 2030.

The global Hereditary Transthyretin Amyloidosis market is expected to grow at a CAGR of 8.9% from 2026 to 2035 to reach $2.28 billion by 2035.

Some Key Players in the Hereditary Transthyretin Amyloidosis market Include, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BridgeBio Pharma Inc., Pfizer Inc., Eli Lilly and Company, Intellia Therapeutics Inc., Regeneron Pharmaceuticals Inc., AstraZeneca plc, Novartis AG, Roche Holding AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Bristol Myers Squibb, Merck and Co Inc., Johnson and Johnson, AbbVie Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Amgen Inc. .

Major trend in this market includes: Innovative RNAi Therapeutics Driving Advancements In The Market. For further insights on this market. request a sample here

North America was the largest region in the hereditary transthyretin amyloidosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary transthyretin amyloidosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us